Dr. Hung T. Khong, MD

Dr. Khong practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Khong's NPI, 1366586521, was assigned on February 19, 2007. Dr. Khong graduated from Temple University School of Medicine in 1994. Dr. Khong holds Arizona license 69177.

Dr. Khong's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Khong also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Khong's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Khong is also affiliated with Banner Gateway Medical Center. The medical group on file is University of Utah Health. Dmand AI also links Dr. Khong to 1 more hospital, 1 breast imaging center, 1 group practice or clinic, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khong practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khong's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Khong's licenses on file in 2 states: Arizona and Utah.

CMS data shows 360 Medicare services from Dr. Khong across 3 procedure codes in 2024, for 113 Medicare patients. Medicare paid $31,748 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 113 Medicare patients who saw Dr. Khong in 2024. The largest group is 65 to 74, with 61 patients. 75% of them have cancer, and 70% have high blood pressure. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khong's median patient age at 66, with 97% women.

In 2024, Dr. Khong wrote 497 Medicare Part D claims for 150 patients. 84% of them were for generic drugs. CMS names the drug for 369 of them, across 13 drugs with 11 or more claims each, at $440,182 in total drug cost. In 2023, CMS named 437 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Khong for performance year 2024, reported as part of a group. Dr. Khong accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Khong as offering telehealth.

Dmand AI links 23 papers to Dr. Khong, published from 2012 to 2023. 2016 was the busiest year, with 4. The most frequent topics are Melanoma, Antineoplastic Combined Chemotherapy Protocols and Breast Neoplasms. Dr. Khong has published most often in Anticancer Res. Dr. Khong's most frequent co-authors are Ricardo Lima Barros Costa, MD, Brian J. Czerniecki, MD and Randy C. Bowen, MD.

Dmand AI links Dr. Khong to 6 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Neoplasms, Male and Triple Negative Breast Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4. Open Payments lists research payments to Dr. Khong that name 1 trial.

CMS Open Payments shows 47 general payments to Dr. Khong from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Eli Lilly and Company paid the most, $8,332. It also lists 9 research payments totaling $9,413 from 2018 to 2022, naming 1 clinical trial.

Dr. Khong graduated from Temple University School of Medicine in 1994.